Search - tctmd.com

Displaying 781 - 800 of 1728

Sort: Relevancy | Date

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

News Conference News TVT 2020

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

Yael L. Maxwell

June 26, 2020

Device Explants After TAVR Rare but Risky

News Conference News TVT 2020

Device Explants After TAVR Rare but Risky

Michael O'Riordan

June 24, 2020

Real-world, Low-risk Patients Fare Well With Self-Expanding Evolut PRO

News Conference News TVT 2020

Real-world, Low-risk Patients Fare Well With Self-Expanding Evolut PRO

June 24, 2020

Late and Early Results in Tune for Melody and Harmony Transcatheter PVs

News Conference News SCAI 2020

Late and Early Results in Tune for Melody and Harmony Transcatheter PVs

May 25, 2020

Permanent Conduction-System Pacing After TAVR? Don’t ‘Diss the His’

News Conference News HRS 2020

Permanent Conduction-System Pacing After TAVR? Don’t ‘Diss the His’

Michael O'Riordan

May 21, 2020

PCI at Ambulatory Surgical Centers: Quality Cannot Suffer, SCAI Says

News Conference News SCAI 2020

PCI at Ambulatory Surgical Centers: Quality Cannot Suffer, SCAI Says

May 18, 2020

Micra Leadless Pacemaker Tied to Fewer Complications in Medicare Patients

News Conference News HRS 2020

Micra Leadless Pacemaker Tied to Fewer Complications in Medicare Patients

May 18, 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

May 15, 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

News Conference News HRS 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

May 13, 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

News Conference News ACC 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

April 06, 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

News Conference News ACC 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

Michael O'Riordan

March 31, 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

News Conference News ACC 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

Yael L. Maxwell

March 31, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.